Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Patrick H. Ruane

Patrick H. Ruane, Redwood City, CA US

Patent application numberDescriptionPublished
20080286325CYCLODEXTRIN ELUTION MEDIA FOR MEDICAL DEVICE COATINGS COMPRISING A TAXANE THERAPEUTIC AGENT - The present disclosure provides methods of measuring the release of a taxane therapeutic agent from a medical device as a function time in contact with a suitable elution medium. The method preferably comprises the step of contacting a coated medical device comprising a taxane therapeutic agent with an elution medium comprising a cyclodextrin to provide an elution profile indicative of the composition or configuration of a medical device coating comprising a taxane therapeutic agent. The elution profile can provide information about the medical device coating that is useful in lot release testing.11-20-2008
20090105686ADJUSTABLE-LENGTH DRUG DELIVERY BALLOON - A drug or agent coated balloon having a length which is adjustable in vivo is described herein. The balloon is configured to be coated or coatable with one or more drugs where the coating may be applied prior to advancement into a patient body or prior to balloon expansion within the patient body. The length of the expandable portion of the balloon is adjustable to approximate a length of the tissue region to be treated. Moreover, the drug-coated balloon may be used alone or it may be utilized to deploy luminal prostheses having one or more linked or otherwise coupled segments.04-23-2009
20110093056Use of Plasma in Formation of Biodegradable Stent Coating - Metallic stents are treated with a gaseous species in a plasma state under conditions causing the species to polymerize and to be deposited in polymerized form on the metallic stent surface prior to the application of a drug-polymer mixture, which is done by conventional non-plasma deposition methods. The drug-polymer mixture once applied forms a coating on the stent surface that releases the drug in a time-release manner and gradually erodes, leaving only the underlying plasma-deposited polymer. In certain cases, the plasma-deposited polymer itself erodes or dissolves into the physiological medium over an extended period of time, leaving only the metallic stent. While the various polymers and drug remain on the stent, the plasma-deposited polymer enhances the adhesion of the drug-polymer anchor coating and maintains the coating intact upon exposure to the mechanical stresses encountered during stent deployment.04-21-2011

Patent applications by Patrick H. Ruane, Redwood City, CA US

Patrick H. Ruane, San Mateo, CA US

Patent application numberDescriptionPublished
20080199510THERMO-MECHANICALLY CONTROLLED IMPLANTS AND METHODS OF USE - An implant comprises a structure that may be implanted into tissue and that has a first material property at normal body temperature. The first material property is variable at elevated temperatures above normal body temperature. The implant also has a plurality of particles dispersed in the structure that are adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to incident radiation raises the temperature of the structure thereby changing the first material property relative to the first material property at normal body temperature.08-21-2008
20090061072MANDREL AND METHOD FOR COATING OPEN-CELL IMPLANTABLE ENDOVASCULAR STRUCTURES - Methods of coating a medical device are provided to improve coating uniformity and reduce coating irregularities while reducing direct coating of the luminal surface of the medical device. Preferably, methods of coating a tubular medical device include the steps of: positioning the tubular medical device around a mandrel coating assembly, mounting the tubular medical device on the mandrel coating assembly and spraying a coating solution including a therapeutic agent and a solvent onto the abluminal surface of the tubular medical device mounted on the mandrel coating assembly. The mandrel coating assembly may include an axial member of a diameter that is less than the diameter of the lumen of the tubular medical device and at least one annular projection extending from the axial member to an outer surface having a diameter greater than or substantially equal to the diameter of the lumen of the medical device. Improved coating uniformity may be achieved by providing an annular space between the luminal surface of the medical device and an axial member. Coating on the luminal surface may be minimized by providing an axial member having an outer diameter that is greater than the maximum width or length of the spray contacting the axial member after passing through the openings in the medical device.03-05-2009
20090177267Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists - This invention relates to medical devices and an angiotensin II type 2 (AT07-09-2009
20090258050Controlled Drug Delivery Using a Zein Layer Modified with Levulinic Acid - The disclosure relates to medical devices coated with zein admixed with levulinic acid. The medical device may further include a therapeutic agent in contact with zein admixed with levulinic acid. Zein admixed with levulinic acid allows the therapeutic agent to be retained on the device during delivery and also controls the elution rate of the therapeutic agent following implantation. The disclosure further relates to methods of delivering a therapeutic agent on said medical devices as well as their use especially in the form of stents for prevention of restenosis.10-15-2009
20110022148THERMO-MECHANICALLY CONTROLLED IMPLANTS AND METHODS OF USE - An implant comprises a structure that may be implanted into tissue and that has a first material property at normal body temperature. The first material property is variable at elevated temperatures above normal body temperature. The implant also has a plurality of particles dispersed in the structure that are adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to incident radiation raises the temperature of the structure thereby changing the first material property relative to the first material property at normal body temperature.01-27-2011
20110153007Taxane Coatings for Implantable Medical Devices - This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired period of time, which can be varied in the absence of a polymer by selecting the type and amount of solid forms of the taxane therapeutic agent in the coating. Other preferred embodiments relate to methods of coating medical devices and methods of treatment. The coatings can provide a sustained release of the taxane therapeutic agent within a body vessel without containing a polymer to achieve the desired rate of paclitaxel elution.06-23-2011

Patent applications by Patrick H. Ruane, San Mateo, CA US